• Home
  • Search Results

Search Results

432 studies match your search
Open

Rehabilitation outcomes study

Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Brain and Other Nervous System, Breast, and 19 more)
Open

Basal-like PDAC treated with Gemcitabine, Erlotinib and nab-paclitaxel (PANGEA).

Are you a patient with advanced basal-like pancreatic adenocarcinoma? If so this could the a Trial for you to as this is a Phase I/II trial is to evaluate the safety, efficacy and tolerability of low-dose EGFR inhibitors in combination with bi-weekly gemcitabine/nab-paclitaxel (GnP) in subjects with basal tumors

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Pancreatic)
Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Uterine (endometrial), Ovarian)
Open

Venetoclax, MLN9708 and Dexamethasone for Relapsed or Refractory Light Chain Amyloidosis

Have you been diagnosed with relapsed or refractory light chain amyloidosis? If so, you may be able to take part in a research study looking at the safety and tolerability of giving Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone to patients with relapsed or refractory light chain amyloidosis.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Other Cancers)
Open

A PHASE 1/2A, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY, AND PHARMACOKINETICS OF REGN10597 (ANTI PD-1-IL2RA-IL2 FUSION PROTEIN) IN PATIENTS WITH ADVANCED SOLID ORGAN MALIGNANCIES

Do you have kidney or bladder cancer. You may be able to participate in a research study to find out if the investigational drug REGN10597 is safe, tolerable, and effective in treating kidney and bladder cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Kidney)
Open

MODERN

Do you have bladder cancer that has spread to nearby tissue or other parts of the body? You may be able to participate in a research study to find out if the investigational drug disitamab vedotin alone or with pembrolizumab works to treat bladder cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder)
Open

Bladder Cancer Study

Do you have bladder cancer and have had your bladder removed? If so, you may be able to take part in a research study to determine if patients need additional treatment called immunotherapy to prevent cancer from coming back.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder)
Coming Soon

Lung Cancer Treatment Study

In this study, we want to see if a new type of medicine for lung cancer treatment is better than the usual treatments. We are curious if this new medicine could improve things for people with lung cancer. This will help us understand if the new medicine will treat people better or faster.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Lung)
Open

AIRPanc - Ph2 Randomized Study Evaluating Patients with advanced Pancreatic Ductal Adenocarcinoma

Have you been diagnosed with pancreatic adenocarcinoma? If so, you may be a good fit to help us learn if combination treatment with specific drugs may stimulate the body's immune system against cancer cells.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Pancreatic)
Open

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Have you been diagnosed with Multiple Myeloma? Have you received idecabtagene vicleucel (ide-cel (Abecma)) CAR-T treatment? If so, you may be able to take part in a research study looking at for how long a new drug called iberdomide will keep Multiple Myeloma under control (in remission).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Multiple Myeloma)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research